Delivery of IL-12p40 ameliorates DSS-induced colitis by suppressing IL-17A expression and inflammation in the intestinal mucosa

Copyright © 2012 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 144(2012), 3 vom: 01. Sept., Seite 190-9
1. Verfasser: Kim, Doo-Jin (VerfasserIn)
Weitere Verfasser: Kim, Kwang-Soon, Song, Mi-Young, Seo, Sang-Hwan, Kim, Su-Jin, Yang, Bo-Gie, Jang, Myoung-Ho, Sung, Young-Chul
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2012
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Interleukin-12 Subunit p40 Interleukin-17 Interleukin-23 Interleukin-12 187348-17-0 Interferon-gamma 82115-62-6 Dextran Sulfate 9042-14-2
Beschreibung
Zusammenfassung:Copyright © 2012 Elsevier Inc. All rights reserved.
IL-12p40 homodimer is a natural antagonist of IL-12 and IL-23, which are potent pro-inflammatory cytokines required for Th1 and Th17 immune responses, respectively. It has been reported that Th17 response is involved in inflammatory bowel disease (IBD), a chronic disorder of the digestive system with steadily increasing incidence. Here, we investigated the effects of IL-12p40 delivered via recombinant adenovirus (rAd/IL-12p40) or mesenchymal stem cells (MSC/IL-12p40) in a dextran sulfate sodium salt (DSS)-induced colitis model. Injection of rAd/IL-12p40 or MSC/IL-12p40 efficiently attenuated colitis symptoms and tissue damage, leading to an increased survival rate. Moreover, IL-12p40 delivery suppressed IL-17A, but enhanced IFN-γ production from mesenteric lymph node cells, supporting the preferential suppression of IL-23 by IL-12p40 homodimer in vitro and the suppression of Th17 responses in vivo. Our results demonstrate that IL-12p40 delivery ameliorates DSS-induced colitis by suppressing IL-17A production and inflammation in the intestinal mucosa, providing an effective new therapeutic strategy for IBDs
Beschreibung:Date Completed 07.11.2012
Date Revised 01.12.2018
published: Print-Electronic
ErratumIn: Clin Immunol. 2012 Nov;145(2):174-5
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2012.06.009